TABLE 2.
Characteristics associated with antibody response
| Univariable | Multivariable | |||
|---|---|---|---|---|
| RR (95% I) | P | RR (95% I) | P | |
| Age (y), median (IQR) | 1.01 (0.98–1.03) | 0.65 | – | – |
| Age (y) | ||||
| <68 | (Reference) | (Reference) | ||
| ≥68 | 1.73 (1.05-2.87) | 0.03 | 3.14 (1.29-7.66) | 0.01 |
| Gender | ||||
| Female | (Reference) | – | – | |
| Male | 0.85 (0.51-1.41) | 0.52 | – | – |
| Ethnicity | ||||
| White | (Reference) | – | – | |
| Black | 0.38 (0.13-1.10) | 0.08 | – | – |
| Hispanic | 0.41 (0.11-1.49) | 0.18 | – | – |
| Asian | 0.91 (0.41-2.04) | 0.82 | – | – |
| Time from transplant to vaccination (y), median (IQR) | 1.08 (1.04–1.12) | <0.001 | 1.07 (1.00–1.15) | 0.045 |
| Time from transplant to vaccination (y) | ||||
| <6 mo | (Reference) | – | – | |
| ≥6 mo | 2.41 (1.18-4.93) | 0.02 | – | – |
| Vaccine | ||||
| Moderna mRNA-1273 | (Reference) | – | – | |
| Pfizer-BioNTech | 0.83 (0.50-1.38) | 0.48 | – | – |
| Days between vaccine 1 and vaccine 2, median (IQR) | 0.99 (0.93–1.05) | 0.66 | – | – |
| Days between vaccine 1 and last lab date, median (IQR) | 1.00 (1.00–1.01) | 0.46 | – | – |
| Days between vaccine 2 and last lab date, median (IQR) | 1.00 (1.00–1.01) | 0.42 | – | – |
| History of rejection | ||||
| No | (Reference) | – | – | |
| Yes | 1.29 (0.75-2.20) | 0.36 | – | – |
| Rejection before or after vaccination (n = 25) | ||||
| Before | (Reference) | – | – | |
| After | 0.70 (0.21-2.40) | 0.58 | – | – |
| Time from transplant to rejection (y), median (IQR) (n = 25) | 1.04 (0.71–1.52) | 0.85 | – | – |
| Immunosuppression therapy and induction | ||||
| T-cell depleting therapy, ≤6 mo | ||||
| No | (Reference) | (Reference) | ||
| Yes | 0.18 (0.03-1.18) | 0.07 | 0.27 (0.04–2.04) | 0.20 |
| Tacrolimus | ||||
| No | (Reference) | – | – | |
| Yes | 0.99 (0.44-2.27) | 0.99 | – | – |
| Mycophenolate | ||||
| No | (Reference) | (Reference) | ||
| Yes | 0.45 (0.29-0.72) | 0.001 | 0.42 (0.21–0.87) | 0.02 |
| Prednisone | ||||
| No | (Reference) | – | – | |
| Yes | 0.40 (0.25-0.63) | <0.001 | – | – |
| Cyclosporine | ||||
| No | (Reference) | – | – | |
| Yes | 1.04 (0.41-2.64) | 0.94 | – | – |
| mTOR inhibitors | ||||
| No | (Reference) | – | – | |
| Yes | 1.84 (1.00-3.36) | 0.048 | – | – |
| Induction | ||||
| No | (Reference) | – | – | |
| Yes | 1.09 (0.42-2.86) | 0.86 | – | – |
| Induction type | ||||
| None | (Reference) | (Reference) | ||
| Thymoglobulin | 1.11 (0.42-2.95) | 0.83 | 2.24 (0.59-8.52) | 0.24 |
| Simulect | 1.00 (0.34-2.95) | 1.00 | 1.65 (0.43-6.35) | 0.47 |
| Campath | 1.50 (0.28-7.93) | 0.63 | 4.91 (0.44-55.09) | 0.20 |
| C-statistic = 0.83 | ||||
Values are in number (%) unless otherwise specified.
IQR, interquartile range; mTOR, mammalian target of rapamycin; RR, relative risk.